Overview
- Editors:
-
-
Barry B. Bercu
-
Pediatric Endocrinology, All Children’s Hospital, St. Petersburg, USA
-
Richard F. Walker
-
Pediatric Endocrinology, All Children’s Hospital, St. Petersburg, USA
Access this book
Other ways to access
Table of contents (27 papers)
-
Novel Aspects of Growth Hormone Research II
-
- Kazuo Chihara, Hidesuke Kaji, Satoko Hayashi, Hiroji Yagi, Yasuhiro Takeshima, Maki Mitani et al.
Pages 223-230
-
- James Wells, Brian Cunningham, Germaine Fuh, Henry Lowman, Mark Ultsch, Bart de Vos
Pages 231-241
-
-
Clinical Application of Growth Hormone Treatment
-
Front Matter
Pages 257-257
-
-
-
- Pinchas Cohen, Jaime Guevara-Aguirre, Paul J. Fielder, Kristin Wilson, Sharron E. Gargosky, Mary A. Vaccarello et al.
Pages 279-285
-
- E. Verena Jorgensen, Dorothy I. Shulman, Frank B. Diamond Jr., Allen W. Root, Barry B. Bercu
Pages 286-298
-
Poster Presentation Manuscripts
-
Front Matter
Pages 299-299
-
- H. Maurice Goodman, G. Peter Frick, Tova Bick, Lih-Ruey Tai, Jack L. Leonard
Pages 301-316
-
- T. Wise, J. Klindt, F. C. Buonomo, J. T. Yen
Pages 317-327
-
- Gian Paolo Ceda, Gian Piero Marzani, Valeria Tontodonati, Emanuela Piovani, Alberto Banchini, Maria Teresa Baffoni et al.
Pages 328-337
-
- F. Strollo, A. Semprini, G. Strollo, M. Morè, L. Bollanti, A. Ciarmatori et al.
Pages 338-346
-
- Andrea Giustina, Anna Rosa Bussi, William B. Wehrenberg
Pages 347-358
-
Back Matter
Pages 359-379
About this book
This book is a compendium of proceedings from the Symposium on Growth Hormone II: Basic and Clinical Aspects. The intent of the sym posium was to review current aspects of the rapidly expanding science of growth hormone (GH) neuroendocrinology, especially those develop ments that occurred since our last meeting in 1985. The meeting was timely since there have been many new and exciting developments in basic research on the GH axis, and several new clinical applications for GH other than growth have been identified. For example, significant strides have been made into use of the bioengineered hormone as an anabolic in debilitated states and as an immunorestorative agent. Both these areas have received most attention as they relate to geriatric popu lations. Furthermore, recent focus on a novel family of GH secretagogues that complement the action of GHRH has shown that in animal models, these compounds have the potential to restore GH secretion in deficient or insufficient states, including growth retardation, obesity, and aging. Accordingly, these xenobiotics may have significant potential as drug products to stimulate physiological GH secretion and, thus, resist or reverse some of the maladaptive changes in form and function resulting from GH insufficiency. The importance of these agents as drug candidates is underscored by the diversity of molecules that have been studied by various pharmaceutical companies and the recent discovery that non peptide analogs with high oral bioavailability can be synthesized.